PDRN and Vitiligo: What It Can and Cannot Do

How PDRN Targets Vitiligo

Most of what is known about PDRN comes from lab, animal and injection studies, and none of it was done in vitiligo. First, anti-inflammatory action: in experimental models PDRN acts on the adenosine A2A receptor and dampens inflammatory signaling, which is one reason it is used for tissue repair. Whether this matters for the autoimmune process in vitiligo is unknown. Second, wound healing: in a rat model, daily PDRN injections sped healing after fractional CO2 laser. That is relevant to post-procedure recovery in general, not to pigment. Third — and this is the important caveat — PDRN works against pigment in the lab. In mouse melanocytes and human melanocyte–keratinocyte cocultures it lowered melanin content, tyrosinase activity and MITF, and in mouse melanoma cells it inhibited tyrosinase and switched down melanin-making genes. A six-patient series even used intradermal PDRN injections to lighten facial hyperpigmentation. For vitiligo, where the goal is to bring pigment back, this means PDRN should not be thought of as a repigmentation aid, and it is sensible to keep it off patches under active repigmentation treatment unless your dermatologist advises otherwise. Repigmentation requires functioning melanocytes responding to medical therapy such as phototherapy, topical immunomodulators or JAK inhibitors. PDRN is generally well tolerated, so as a soothing ingredient on irritated, unaffected skin it is a reasonable option — but it is supportive skin care, not vitiligo treatment.

It is important to be clear from the outset that PDRN (polydeoxyribonucleotide) is not a cure for vitiligo and does not repigment skin. There is also a specific reason for caution: in cell studies, PDRN reduced melanin production and tyrosinase activity in pigment cells, and a small clinical series used intradermal PDRN injections to lighten facial hyperpigmentation. Repigmentation is the opposite goal. Nothing in the current evidence suggests PDRN helps vitiligo patches regain color, and whether it could work against repigmentation has not been studied. Any role for PDRN belongs at most in gentle supportive skin care, and only with your dermatologist’s agreement.

The use most often discussed is recovery after procedures that deliberately injure the skin, such as microneedling or fractional laser, which some dermatologists combine with phototherapy in stable disease. Studies of injected PDRN show faster wound healing, including after fractional laser in a rat model, but no study has tested PDRN in vitiligo, and its anti-pigment effect in the lab makes it a poor fit for patches under treatment. For people living with vitiligo, PDRN is best seen as an optional, well-tolerated soothing ingredient for general skin comfort — never a substitute for dermatologist-directed treatment, and not something to apply to patches you are trying to repigment without asking your dermatologist first.